Roivant Sciences Ltd. 13D and 13G filings for Arbutus Biopharma Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-25 07:19 am Unchanged | 2025-02-21 | 13D | Arbutus Biopharma Corporation ABUS | Roivant Sciences Ltd. ROIV | 38,847,462 20.500% | 0 (Unchanged) | Filing |
| 2025-02-18 5:21 pm Unchanged | 2025-02-18 | 13D | Arbutus Biopharma Corporation ABUS | Roivant Sciences Ltd. ROIV | 38,847,462 20.500% | 0 (Unchanged) | Filing |
| 2021-10-20 5:13 pm Purchase | 2021-10-18 | 13D | Arbutus Biopharma Corporation ABUS | Roivant Sciences Ltd. ROIV | 38,847,462 29.100% | 22,833,922 (+142.59%) | Filing |